-
Article
Open AccessALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma
Osteosarcoma (OS) remains a dismal malignancy in children and young adults, with poor outcome for metastatic and recurrent disease. Immunotherapies in OS are not as promising as in some other cancer types due ...
-
Article
Open AccessCharacterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination
This clinical trial evaluated a novel telomerase-targeting therapeutic cancer vaccine, UV1, in combination with ipilimumab, in patients with metastatic melanoma. Translational research was conducted on patient...
-
Article
Open AccessCorrection to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
The original version of this article unfortunately included a mistake in Fig. 2b where the images of mice in the tumour control group (right), day 30 (bottom) should be removed as the wrong images (duplicate o...
-
Article
Open AccessPreclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
Off-target toxicity due to the expression of target antigens in normal tissue or TCR cross-reactivity represents a major risk when using T cell receptor (TCR)-engineered T cells for treatment of solid tumours....
-
Article
Open AccessA TCR-based Chimeric Antigen Receptor
Effector T cells equipped with engineered antigen receptors specific for cancer targets have proven to be very efficient. Two methods have emerged: the Chimeric Antigen Receptors (CARs) and T-cell Receptor (TC...
-
Article
Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer
In newly diagnosed metastatic hormone-naive prostate cancer (mPC), telomerase-based immunotherapy with the novel hTERT peptide vaccine UV1 can induce immune responses with potential clinical benefit. This phas...
-
Article
Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination
We have previously reported two trials in non-small cell lung cancer (NSCLC) evaluating vaccine therapy with the telomerase peptide GV1001. The studies demonstrated considerable differences in survival among i...
-
Article
Therapeutic vaccines for cancer: an overview of clinical trials
Development of vaccines for the treatment of cancer has posed many challenges, but results from some recent studies have confirmed the potential for clinical b...
-
Article
Open AccessTherapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
The growth and recurrence of several cancers appear to be driven by a population of cancer stem cells (CSCs). Glioblastoma, the most common primary brain tumor, is invariably fatal, with a median survival of a...
-
Article
Open AccessIn vitro and in vivo properties of CD133 expressing cells from human lung cancer cell lines
Tumor development is recently hypothesized to depend on a rare cell population with stem cell properties, such cells are called cancer stem cells (CSCs) or tumor-initiating cells (TICs). From various cancer ti...
-
Article
Vaccination of patients with cutaneous melanoma with telomerase-specific peptides
A phase I study was conducted to investigate the safety, tolerability, and immunological responses to vaccination with a combination of telomerase-derived peptides GV1001 (hTERT: 611–626) and p540 (hTERT: 540–...
-
Article
Open AccesshTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
Immunotherapy targeting the hTERT subunit of telomerase has been shown to induce robust immune responses in cancer patients after vaccination with single hTERT peptides. Vaccination with dendritic cells (DCs) ...
-
Article
Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination
Cancer vaccine trials frequently report on immunological responses, without any clinical benefit. This paradox may reflect the challenge of discriminating between effective and pointless immune responses and s...
-
Article
Open AccessA full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines
Dendritic cells (DCs) are professional antigen-presenting cells with the ability to induce primary T-cell responses and are commonly produced by culturing monocytes in the presence of IL-4 and GM-CSF for 5–7 d...
-
Article
T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells
We have developed an individualized melanoma vaccine based on autologous dendritic cells (DCs) transfected with autologous tumor-mRNA. The vaccine targets the unique spectrum of tumor antigens in each patient ...
-
Article
Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer
Purpose: A phase I/II study was conducted to investigate the safety, tolerability and clinical response to vaccination with a combination of telomerase peptides GV1001 (hTERT: 611–626) an...
-
Article
Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells
We have developed immuno-gene therapy for malignant melanoma and prostate cancer. The therapy is based on monocyte-derived dendritic cells (DCs) that are transfected with autologous melanoma-mRNA or mRNA from ...
-
Article
Open AccessCharacterization of novel alternative splicing sites in human telomerase reverse transcriptase (hTERT): analysis of expression and mutual correlation in mRNA isoforms from normal and tumour tissues
Human telomerase reverse transcriptase (hTERT) is a key component for synthesis and maintenance of telomeres on chromosome ends and is required for the continued proliferation of cells. Estimation of hTERT expres...
-
Article
Preclinical evaluation of autologous dendritic cells transfected with mRNA or loaded with apoptotic cells for immunotherapy of high-risk neuroblastoma
Children with high-risk neuroblastoma (NB) have a poor clinical outcome. The purpose of the present study was to evaluate different strategies for immunotherapy of high-risk NB based on vaccination with antige...
-
Article
Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination
Most cancer vaccines to date have made use of common tumor antigens or allogenic cancer cell lines. The majority of tumor antigens may, however, be unique patient-specific antigens. Dendritic cells (DCs) are t...
